California State Teachers Retirement System cut its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 9.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 62,886 shares of the company’s stock after selling 6,690 shares during the period. California State Teachers Retirement System’s holdings in Pacira Pharmaceuticals were worth $2,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Oppenheimer Asset Management Inc. bought a new position in shares of Pacira Pharmaceuticals in the second quarter worth $114,000. Cubist Systematic Strategies LLC grew its stake in shares of Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after purchasing an additional 1,752 shares in the last quarter. QS Investors LLC bought a new position in shares of Pacira Pharmaceuticals in the second quarter worth $157,000. Ameritas Investment Partners Inc. grew its stake in shares of Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after purchasing an additional 302 shares in the last quarter. Finally, Spectrum Management Group Inc. bought a new position in shares of Pacira Pharmaceuticals in the third quarter worth $166,000.

Pacira Pharmaceuticals, Inc. (PCRX) opened at $41.50 on Monday. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The firm has a market capitalization of $1,680.00, a PE ratio of -31.68 and a beta of 2.20. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter last year, the business posted $0.20 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. equities analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current fiscal year.

In related news, CEO David M. Stack sold 58,885 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $6,102,347.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kristen Marie Williams sold 10,000 shares of the stock in a transaction on Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The disclosure for this sale can be found here. Insiders have sold 98,960 shares of company stock valued at $3,868,341 in the last ninety days. Company insiders own 6.60% of the company’s stock.

Several research analysts have recently issued reports on the company. Canaccord Genuity set a $46.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, January 4th. Royal Bank of Canada reissued a “buy” rating and issued a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, October 13th. HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Oppenheimer reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Finally, JPMorgan Chase & Co. assumed coverage on Pacira Pharmaceuticals in a research note on Monday, December 18th. They issued a “neutral” rating and a $47.00 price target for the company. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $49.00.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/california-state-teachers-retirement-system-has-2-36-million-holdings-in-pacira-pharmaceuticals-inc-pcrx/1807683.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.